Pierluigi Simonato
University of Hertfordshire
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Pierluigi Simonato.
Human Psychopharmacology-clinical and Experimental | 2012
Ornella Corazza; Fabrizio Schifano; Pierluigi Simonato; Suzanne Fergus; Sulaf Assi; Jacqueline L. Stair; John Corkery; Giuseppina Trincas; Paolo Deluca; Zoe Davey; Ursula Blaszko; Zsolt Demetrovics; Jacek Moskalewicz; Aurora Enea; Giuditta di Melchiorre; Barbara Mervó; Lucia Di Furia; Magí Farré; Liv Flesland; Manuela Pasinetti; Cinzia Pezzolesi; Agnieszka Pisarska; Harry Shapiro; Holger Siemann; Arvid Skutle; Elias Sferrazza; Marta Torrens; Peer van der Kreeft; Daniela Zummo; Norbert Scherbaum
On the basis of the material available both in the scientific literature and on the web, this paper aims to provide a pharmacological, chemical and behavioural overview of the novel compound methoxetamine. This is a dissociative drug related to ketamine, with a much longer duration of action and intensity of effects. A critical discussion of the availability of information on the web of methoxetamine as a new recreational trend is here provided. Those methodological limitations, which are intrinsically associated with the analysis of online, non‐peer reviewed, material, are here discussed as well. It is concluded that the online availability of information on novel psychoactive drugs, such as methoxethanine, may constitute a pressing public health challenge. Better international collaboration levels and novel forms of intervention are necessary to tackle this fast‐growing phenomenon. Copyright
Human Psychopharmacology-clinical and Experimental | 2013
Ornella Corazza; Sulaf Assi; Pierluigi Simonato; John Corkery; Francesco Saverio Bersani; Zsolt Demetrovics; Jacqueline L. Stair; Suzanne Fergus; Cinzia Pezzolesi; Manuela Pasinetti; Paolo Deluca; Colin Drummond; Zoe Davey; Ursula Blaszko; Jacek Moskalewicz; Barbara Mervó; Lucia Di Furia; Maggi Farre; Liv Flesland; Agnieszka Pisarska; Harry Shapiro; Holger Siemann; Arvid Skutle; Elias Sferrazza; Marta Torrens; F. Sambola; Peer van der Kreeft; Norbert Scherbaum; Fabrizio Schifano
The recent emergence of new psychoactive compounds (novel psychoactive substances (NPS)) has raised prominent challenges in the fields of drug policy, substance use research, public health and service provision. The Recreational Drugs European Network project, funded by the European Commission, was implemented to improve the information stream to young people and professionals about effects/risks of NPS by identifying online products and disseminating relevant information through technological tools.
BioMed Research International | 2014
Francesco Saverio Bersani; Ornella Corazza; Gabriella Albano; Giuseppe Valeriani; Rita Santacroce; Flaminia Bolzan Mariotti Posocco; E. Cinosi; Pierluigi Simonato; Giovanni Martinotti; Giuseppe Bersani; Fabrizio Schifano
Introduction. The use of novel psychoactive substances (NPSs) has rapidly increased as well as their online availability. The aim of this paper is to provide a comprehensive review of the nature and the risks associated with 25C-NBOMe, which has recently appeared in the drug market. Methods. A systematic analysis of the scientific literature and a qualitative assessment of online and media resources (e.g., e-newsgroups, chat-rooms, and e-newsletters) in 10 languages were carried out. Results. 25C-NBOMe is sold online as legal LSD or as research chemical with different designations such as “Boom,” “Pandora,” “Holland film,” or “N-bomb.” It is a partial agonist of 5-HT2A receptors. It is usually ingested orally/sublingually and, less commonly, nasally, through injection, vaginally, rectally, and smoked. Its effects include sublingual numbing, stimulation, “body high,” hallucinations, dissociation, and anxiety. 25C-NBOMe presents high risk of overdoses; acute toxicity and fatalities have been reported. Conclusions. 25C-NBOMe consumption represents an emerging phenomenon with potential harmful effects. Its use is increased by its online availability at low costs. Health and other professionals should be informed about this new trend of substance use.
BioMed Research International | 2015
E. Cinosi; Giovanni Martinotti; Pierluigi Simonato; Darshan Singh; Zsolt Demetrovics; Andres Roman-Urrestarazu; Francesco Saverio Bersani; Balasingam Vicknasingam; Giulia Piazzon; Jih-Heng Li; Wen Jing Yu; Máté Kapitány-Fövény; Judit Farkas; Massimo Di Giannantonio; Ornella Corazza
The use of substances to enhance human abilities is a constant and cross-cultural feature in the evolution of humanity. Although much has changed over time, the availability on the Internet, often supported by misleading marketing strategies, has made their use even more likely and risky. This paper will explore the case of Mitragyna speciosa Korth. (kratom), a tropical tree used traditionally to combat fatigue and improve work productivity among farm populations in Southeast Asia, which has recently become popular as novel psychoactive substance in Western countries. Specifically, it (i) reviews the state of the art on kratom pharmacology and identification; (ii) provides a comprehensive overview of kratom use cross-culturally; (iii) explores the subjective experiences of users; (iv) identifies potential risks and side-effects related to its consumption. Finally, it concludes that the use of kratom is not negligible, especially for self-medication, and more clinical, pharmacological, and socioanthropological studies as well as a better international collaboration are needed to tackle this marginally explored phenomenon.
Human Psychopharmacology-clinical and Experimental | 2017
Roisin Mooney; Pierluigi Simonato; Risha Ruparelia; Andres Roman-Urrestarazu; Giovanni Martinotti; Ornella Corazza
The strive for perfection is prevalent in the fitness industry. This study aimed to explore the use of products to enhance performance alongside exposure to exercise addiction, appearance anxiety and self‐esteem in fitness settings.
Human Psychopharmacology-clinical and Experimental | 2012
Ornella Corazza; Fabrizio Schifano; Pierluigi Simonato; Suzanne Fergus; Sulaf Assi; Jacqueline L. Stair; John Corkery; Giuseppina Trincas; Paolo Deluca; Zoe Davey; Ursula Blaszko; Zsolt Demetrovics; Jacek Moskalewicz; Magí Farré; Liv Flesland; Manuela Pasinetti; Cinzia Pezzolesi; Agnieszka Pisarska; Harry Shapiro; Holger Siemann; Arvid Skutle; Aurora Enea; Giuditta di Melchiorre; Elias Sferrazza; Marta Torrens; Peer van der Kreeft; Daniela Zummo; Norbert Scherbaum
On the basis of the material available both in the scientific literature and on the web, this paper aims to provide a pharmacological, chemical and behavioural overview of the novel compound methoxetamine. This is a dissociative drug related to ketamine, with a much longer duration of action and intensity of effects. A critical discussion of the availability of information on the web of methoxetamine as a new recreational trend is here provided. Those methodological limitations, which are intrinsically associated with the analysis of online, non‐peer reviewed, material, are here discussed as well. It is concluded that the online availability of information on novel psychoactive drugs, such as methoxethanine, may constitute a pressing public health challenge. Better international collaboration levels and novel forms of intervention are necessary to tackle this fast‐growing phenomenon. Copyright
Human Psychopharmacology-clinical and Experimental | 2017
Pierluigi Simonato; Francesco Saverio Bersani; Rita Santacroce; E. Cinosi; Fabrizio Schifano; Giuseppe Bersani; Giovanni Martinotti; Ornella Corazza
The diffusion of novel psychoactive substances (NPSs), combined with the ability of the Internet to act as an online marketplace, has led to unprecedented challenges for governments, health agencies, and substance misuse services. Despite increasing research, there is a paucity of reliable information available to professionals working in the field. The paper will present the pilot results of the first mobile application (SMAIL) for rapid information sharing on NPSs among health professionals.
Human Psychopharmacology-clinical and Experimental | 2012
Ornella Corazza; Fabrizio Schifano; Pierluigi Simonato; Suzanne Fergus; Sulaf Assi; Jacqueline L. Stair; John Corkery; Giuseppina Trincas; Paolo Deluca; Zoe Davey; Ursula Blaszko; Zsolt Demetrovics; Jacek Moskalewicz; Aurora Enea; Giuditta di Melchiorre; Barbara Mervó; Lucia Di Furia; Magí Farré; Liv Flesland; Manuela Pasinetti; Cinzia Pezzolesi; Agnieszka Pisarska; Harry Shapiro; Holger Siemann; Arvid Skutle; Elias Sferrazza; Marta Torrens; Peer van der Kreeft; Daniela Zummo; Norbert Scherbaum
On the basis of the material available both in the scientific literature and on the web, this paper aims to provide a pharmacological, chemical and behavioural overview of the novel compound methoxetamine. This is a dissociative drug related to ketamine, with a much longer duration of action and intensity of effects. A critical discussion of the availability of information on the web of methoxetamine as a new recreational trend is here provided. Those methodological limitations, which are intrinsically associated with the analysis of online, non‐peer reviewed, material, are here discussed as well. It is concluded that the online availability of information on novel psychoactive drugs, such as methoxethanine, may constitute a pressing public health challenge. Better international collaboration levels and novel forms of intervention are necessary to tackle this fast‐growing phenomenon. Copyright
Human Psychopharmacology-clinical and Experimental | 2013
Pierluigi Simonato; Ornella Corazza; Paolo Santonastaso; John Corkery; Paolo Deluca; Zoe Davey; Ursula Blaszko; Fabrizio Schifano
Rivista Di Psichiatria | 2014
Ornella Corazza; Pierluigi Simonato; John Corkery; Giuseppina Trincas; Fabrizio Schifano